Pulmonology

Insights from Lungcast Interviews with Experts Leading the Charge in Detection and Therapy

In this video, the last in a 6-part series, panelists discuss the potential future impact of biologics in the COPD field.

In this video, the fifth in a 6-part series, panelists discuss the factors that influence initiating biologics for COPD.

In this video, the fourth in a 6-part series, panelists discuss how future studies of monoclonal antibodies in COPD could be refined.

In this video, the third in a 6-part series, panelists discuss how learnings from asthma management are informing COPD management.

In this video, the second in a 6-part series, panelists discuss using monoclonal antibodies in early-line COPD treatment.

In this video, the first in a 6-part series, panelists discuss the impact of monoclonal antibodies for COPD management.

Experts discuss the evolving management of asthma and COPD.

New research finds patients with severe allergic asthma had greater emotional regulation than those with venom anaphylaxis, despite reporting poorer physical well-being.

RSV hospitalizations in older adults lead to worse health outcomes and increased cardiovascular risks, highlighting the need for vaccination and monitoring.

Post-COVID CT guidance favors low-dose imaging, clear terms, and precise timing.

This episode of Lungcast features a discussion on the connection between diet, gut microbiome and lung health.

Genentech reveals mixed results for astegolimab in COPD trials, highlighting challenges in treatment options for this serious respiratory disease.

An audio recap of the top 5 stories in healthcare news from the week of 07/07-07/13.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and designations as well as new clinical trial data, in this week's essential news roundup.

Endeavor BioMedicines' Taladegib gains orphan drug status for idiopathic pulmonary fibrosis, showing promise in improving lung function and patient outcomes.

In a new study, Yale researchers develop a method that has the potential to cure cystic fibrosis prior to birth.

Yale researchers developed an AI model that illuminates critical details about—and possible treatments for—idiopathic pulmonary fibrosis. It could do so for many other diseases.

Explore how advanced practice practitioners enhance COPD care through innovative models, improving patient outcomes and addressing rural healthcare challenges.

Discover how recent advancements in biologic therapies transform severe asthma treatment, emphasizing personalized care and the importance of biomarker-driven decisions.

Explore the latest advancements in pulmonology, including FDA approvals and breakthrough therapies for COPD, PAH, and rare respiratory diseases.

Q2 2025 saw new therapies approved for a number of rare disease indications, multiple of which serve as the first disease-modifying therapies in the landscape.

Q2 2025 saw new therapies approved for rare rheumatological conditions and exciting research out of EULAR.

Q2 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

June 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.